Wenqing Yao 4

Accession 0001209191-20-041572

CIK 0000879169other

Filed

Jul 6, 8:00 PM ET

Accepted

Jul 7, 7:30 PM ET

Size

22.7 KB

Accession

0001209191-20-041572

Form 4

Period: 2020-07-02

Ex VP Discovery Medicinal Chem

Transactions

Sale
Common Stock
2020-07-06$107.32/sh−905$97,125→ 156,258 total
Sale
Common Stock
2020-07-06$107.32/sh−15,648$1,679,343→ 156,258 total
Tax Payment
Common Stock
2020-07-06$107.79/sh−404$43,547→ 156,258 total
Exercise/Conversion
Common Stock
2020-07-06$64.55/sh+15,648$1,010,078→ 171,906 total
Award
Employee Stock Option (right to buy)
2020-07-02+12,743→ 12,743 total
Exercise: $106.47Exp: 2030-07-01→ Common Stock (12,743 underlying)
Exercise/Conversion
Common Stock
2020-07-06$64.55/sh+905$58,418→ 157,163 total
Exercise/Conversion
Incentive Stock Option (right to buy)
2020-07-06−905→ 0 total
Exercise: $64.55Exp: 2021-01-20→ Common Stock (905 underlying)
Exercise/Conversion
Non-Qualified Stock Option (right to buy)
2020-07-06−15,648→ 0 total
Exercise: $64.55Exp: 2021-01-20→ Common Stock (15,648 underlying)
Award
Common Stock
2020-07-02+6,661→ 158,849 total
Tax Payment
Common Stock
2020-07-02$106.47/sh−2,187$232,850→ 156,662 total

Footnotes (8)

[F1]Represents award of restricted stock units ("RSUs") that will vest 25% annually over four years, subject to Wenqing Yao's continued service with the issuer through the applicable vesting dates. The RSUs may be settled only for shares of common stock on a one-for-one basis.
[F2]Represents shares withheld automatically by the Issuer to satisfy tax withholding obligations due at settlement of restricted stock units or earned performance shares previously reported in Table I as common stock.
[F3]This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by reporting person.
[F4]Represents weighted average sale price. Actual sale prices ranged from $105.66 - $108.48
[F5]Reporting person undertakes to provide upon request by Securites and Exchange Commission, the issuer or a securityholder of the issuer detailed information regarding the price and number of shares sold within range indicated.
[F6]Including the July 2, 2020 Restricted Stock Unit Grant, this includes an aggregate of 96,857 shares of common stock issuable pursuant to previously reported restricted stock units and earned performance shares that have not vested.
[F7]Beginning July 2, 2020, options become exercisable in 37 installments, with the first 25% vesting after one year and the remainder vesting monthly over three years.
[F8]Beginning January 21, 2014, options become exercisable in 25 installments, with the first 33.33% vesting after one year and the remainder vesting monthly over two years.

Documents

1 file

INCYTE CORP

CIK 0000879169

Entity typeother